N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity

Journal of Medicinal Chemistry

Volumn 58, Issue 18, 2015, Pages 7224-7240

  Nuti, Elisa ^a   Cantelmo, Anna Rita ^b   Gallo, Cristina ^c   Bruno, Antonino ^b   Bassani, Barbara ^b   Camodeca, Caterina ^d   Tuccinardi, Tiziano ^a   Vera, Laura ^e   Orlandini, Elisabetta ^a   Nencetti, Susanna ^a   Stura, Enrico A ^e   Martinelli, Adriano ^a   Dive, Vincent ^e   Albini, Adriana ^c   Rossello, Armando ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,3 DIOXOISOINDOLIN 2 YL) N HYDROXY 2 (N ISOPROPOXY 4' METHOXYBIPHENYL 4 YLSULFONAMIDO)BUTANAMIDE; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE INHIBITOR; N O ISOPROPYL SULFONAMIDO DERIVATIVE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; SULFONAMIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; UMBILICAL VEIN ENDOTHELIAL CELL; X RAY CRYSTALLOGRAPHY; ANIMAL; CELL MOTION; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MOLECULAR DOCKING SIMULATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84942346084     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00367     Document Type: Article

References (54)

1. Stetler-Stevenson, W. G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention J. Clin. Invest. 1999, 103, 1237-1241 10.1172/JCI6870
2. Correa de Sampaio, P.; Auslaender, D.; Krubasik, D.; Failla, A. V.; Skepper, J. N.; Murphy, G.; English, W. R. A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis PLoS One 2012, 7, e30753 10.1371/journal.pone.0030753
3. Rundhaug, J. E. Matrix metalloproteinases and angiogenesis J. Cell. Mol. Med. 2005, 9, 267-285 10.1111/j.1582-4934.2005.tb00355.x
4. Fang, J.; Shing, Y.; Wiederschain, D.; Yan, L.; Butterfield, C.; Jackson, G.; Harper, J.; Tamvakopoulos, G.; Moses, M. A. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 3884-3889 10.1073/pnas.97.8.3884
5. Deryugina, E. I.; Quigley, J. P. Matrix metalloproteinases and tumor metastasis Cancer Metastasis Rev. 2006, 25, 9-34 10.1007/s10555-006-7886-9
6. Basile, J. R.; Holmbeck, K.; Bugge, T. H.; Gutkind, J. S. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D J. Biol. Chem. 2007, 282, 6899-6905 10.1074/jbc.M609570200
7. Sato, H.; Takino, T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion Cancer Sci. 2010, 101, 843-847 10.1111/j.1349-7006.2010.01498.x
8. Devy, L.; Huang, L.; Naa, L.; Yanamandra, N.; Pieters, H.; Frans, N.; Chang, E.; Tao, Q.; Vanhove, M.; Lejeune, A.; van Gool, R.; Sexton, D. J.; Kuang, G.; Rank, D.; Hogan, S.; Pazmany, C.; Ma, Y. L.; Schoonbroodt, S.; Nixon, A. E.; Ladner, R. C.; Hoet, R.; Henderikx, P.; Tenhoor, C.; Rabbani, S. A.; Valentino, M. L.; Wood, C. R.; Dransfield, D. T. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis Cancer Res. 2009, 69, 1517-1526 10.1158/0008-5472.CAN-08-3255
9. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 2002, 295, 2387-2392 10.1126/science.1067100
10. Brown, S.; Bernardo, M. M.; Li, Z. H.; Kotra, L. P.; Tanaka, Y.; Fridman, R.; Mobashery, S. Potent and selective mechanism-based inhibition of gelatinases J. Am. Chem. Soc. 2000, 122, 6799-6800 10.1021/ja001461n
11. Bonfil, R. D.; Sabbota, A.; Nabha, S.; Bernardo, M. M.; Dong, Z.; Meng, H.; Yamamoto, H.; Chinni, S. R.; Lim, I. T.; Chang, M.; Filetti, L. C.; Mobashery, S.; Cher, M. L.; Fridman, R. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor Int. J. Cancer 2006, 118, 2721-2726 10.1002/ijc.21645
12. Kruger, A.; Arlt, M. J. E.; Gerg, M.; Kopitz, C.; Bernardo, M. M.; Chang, M.; Mobashery, S.; Fridman, R. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor Cancer Res. 2005, 65, 3523-3526 10.1158/0008-5472.CAN-04-3570
13. Hoffman, A.; Qadri, B.; Frant, J.; Katz, Y.; Bhusare, S. R.; Breuer, E.; Hadar, R.; Reich, R. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor - synthesis and pharmacodynamic and pharmacokinetic analysis J. Med. Chem. 2008, 51, 1406-1414 10.1021/jm701087n
14. Remacle, A. G.; Golubkov, V. S.; Shiryaev, S. A.; Dahl, R.; Stebbins, J. L.; Chernov, A. V.; Cheltsov, A. V.; Pellecchia, M.; Strongin, A. Y. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth Cancer Res. 2012, 72, 2339-2349 10.1158/0008-5472.CAN-11-4149
15. Rossello, A.; Nuti, E.; Carelli, P.; Orlandini, E.; Macchia, M.; Nencetti, S.; Zandomeneghi, M.; Balzano, F.; Uccello Barretta, G.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP Bioorg. Med. Chem. Lett. 2005, 15, 1321-1326 10.1016/j.bmcl.2005.01.024
16. Tuccinardi, T.; Martinelli, A.; Nuti, E.; Carelli, P.; Balzano, F.; Uccello-Barretta, G.; Murphy, G.; Rossello, A. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides Bioorg. Med. Chem. 2006, 14, 4260-4276 10.1016/j.bmc.2006.01.056
17. Gabelloni, P.; Da Pozzo, E.; Bendinelli, S.; Costa, B.; Nuti, E.; Casalini, F.; Orlandini, E.; Da Settimo, F.; Rossello, A.; Martini, C. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma Neuroscience 2010, 168, 514-522 10.1016/j.neuroscience.2010.03.064
18. Nuti, E.; Casalini, F.; Avramova, S. I.; Santamaria, S.; Cercignani, G.; Marinelli, L.; La Pietra, V.; Novellino, E.; Orlandini, E.; Nencetti, S.; Tuccinardi, T.; Martinelli, A.; Lim, N. H.; Visse, R.; Nagase, H.; Rossello, A. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis J. Med. Chem. 2009, 52, 4757-4773 10.1021/jm900261f
19. Nuti, E.; Casalini, F.; Avramova, S. I.; Santamaria, S.; Fabbi, M.; Ferrini, S.; Marinelli, L.; La Pietra, V.; Limongelli, V.; Novellino, E.; Cercignani, G.; Orlandini, E.; Nencetti, S.; Rossello, A. Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models J. Med. Chem. 2010, 53, 2622-2635 10.1021/jm901868z
20. Nuti, E.; Casalini, F.; Santamaria, S.; Fabbi, M.; Carbotti, G.; Ferrini, S.; Marinelli, L.; La Pietra, V.; Novellino, E.; Camodeca, C.; Orlandini, E.; Nencetti, S.; Rossello, A. Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models J. Med. Chem. 2013, 56, 8089-8103 10.1021/jm4011753
21. Rossello, A.; Nuti, E.; Orlandini, E.; Carelli, P.; Rapposelli, S.; Macchia, M.; Minutolo, F.; Carbonaro, L.; Albini, A.; Benelli, R.; Cercignani, G.; Murphy, G.; Balsamo, A. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) Bioorg. Med. Chem. 2004, 12, 2441-2450 10.1016/j.bmc.2004.01.047
22. Rossello, A.; Nuti, E.; Orlandini, E.; Balsamo, A.; Tuccinardi, T. Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors. PCT WO2008113756, 2008.
23. 2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme Anal. Biochem. 2004, 328, 166-173 10.1016/j.ab.2003.12.035
24. Becker, D. P.; Barta, T. E.; Bedell, L. J.; Boehm, T. L.; Bond, B. R.; Carroll, J.; Carron, C. P.; DeCrescenzo, G. A.; Easton, A. M.; Freskos, J. N.; Funckes-Shippy, C. L.; Heron, M.; Hockerman, S.; Howard, C. P.; Kiefer, J. R.; Li, M. H.; Mathis, K. J.; McDonald, J. J.; Mehta, P. P.; Munie, G. E.; Sunyer, T.; Swearingen, C. A.; Villamil, C. I.; Welsch, D.; Williams, J. M.; Yu, Y.; Yao, J. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease J. Med. Chem. 2010, 53, 6653-6680 10.1021/jm100669j
25. Overall, C. M.; Kleifeld, O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nat. Rev. Cancer 2006, 6, 227-239 10.1038/nrc1821
26. Deryugina, E. I.; Quigley, J. P. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature Matrix Biol. 2015, 44-46, 94-112 10.1016/j.matbio.2015.04.004
27. Rossello, A.; Nuti, E. Drug design of sulfonylated MMP inhibitors. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Wiley Series in Drug Discovery and Development; Wang, B., Series Ed.; John Wiley & Sons, Inc.: New York, 2009; pp 549-589.
28. Kawasaki, Y.; Xu, Z. Z.; Wang, X.; Park, J. Y.; Zhuang, Z. Y.; Tan, P. H.; Gao, Y. J.; Roy, K.; Corfas, G.; Lo, E. H.; Ji, R. R. Distinct roles of matrix metalloproteases in the early and late phase development of neuropathic pain Nat. Med. 2008, 14, 331-336 10.1038/nm1723
29. Warpehoski, M. A.; Mitchell, M. A.; Jacobsen, E. J. J.; α-Amino sulfonyl hydroxamic acids as metalloproteinase inhibitors. US 5804593, 1998.
30. Subramaniam, R.; Haldar, M. K.; Tobwala, S.; Ganguly, B.; Srivastava, D. K.; Mallik, S. Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 3333-3337 10.1016/j.bmcl.2008.04.035
31. Jacobsen, E. J. J.; Skaletzky, L. L. Bis-sulfonamides hydroxamic acids as MMP inhibitors. US 5859061, 1999.
32. Ma, D.; Wu, W.; Yang, G.; Li, J.; Li, J.; Ye, Q. Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 47-50 10.1016/j.bmcl.2003.10.026
33. Cheng, X. C.; Wang, Q.; Fang, H.; Tang, W.; Xu, W. F. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors Bioorg. Med. Chem. 2008, 16, 7932-7938 10.1016/j.bmc.2008.07.073
34. Hiruma, T.; Kobayashi, K.; Inomata, S. Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation. EP1452527, 2002.
35. Albini, A.; Iwamoto, Y.; Kleinman, H. K.; Martin, G. R.; Aaronson, S. A.; Kozlowski, J. M.; McEwan, R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells Cancer Res. 1987, 47, 3239-3245
36. Albini, A.; Benelli, R. The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation Nat. Protoc. 2007, 2, 504-511 10.1038/nprot.2006.466
37. Albini, A.; Fontanini, G.; Masiello, L.; Tacchetti, C.; Bigini, D.; Luzzi, P.; Noonan, D. M.; Stetler-Stevenson, W. G. Angiogenic potential in vivo by Kaposis sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2 AIDS 1994, 8, 1237-1244 10.1097/00002030-199409000-00004
38. SoftMax Pro 4.7.1; Molecular Devices: Sunnyvale, CA, 2004.
39. GraFit version 4; Erithecus Software: Staines, Middlesex, UK, 1998.
40. Carpentier, G. Contribution: Angiogenesis Analyzer. ImageJ. News http://imagej.nih.gov/ij/notes.html, 2012
41. Rozen, S.; Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers Methods Mol. Biol. 1999, 132, 365-386 10.1385/1-59259-192-2:365
42. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 10.1093/nar/28.1.235
43. Case, D. A.; Darden, T. A., III; Cheatham, T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M.; Roberts, B.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Liu, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.; Wang, J.; Hsieh, M.-J.; Cui, G.; Roe, D. R.; Mathews, D. H.; Seetin, M. G.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. A. AMBER, version 11; University of California: San Francisco, CA, 2010.
44. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J. Comput. Chem. 1998, 19, 1639-1662 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
45. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility J. Comput. Chem. 2009, 30, 2785-2791 10.1002/jcc.21256
46. York, D. M.; Darden, T. A.; Pedersen, L. G. The effect of long range electrostatic interactions in simulations of macromolecular crystals: a comparison of the Ewald and truncated list methods J. Chem. Phys. 1993, 99, 8345-8348 10.1063/1.465608
47. Vera, L.; Antoni, C.; Devel, L.; Czarny, B.; Cassar-Lajeunesse, E.; Rossello, A.; Dive, V.; Stura, E. A. Screening Using Polymorphs for the Crystallization of Protein-Ligand Complexes Cryst. Growth Des. 2013, 13, 1878-1888 10.1021/cg301537n
48. Vera, L.; Stura, E. A. Strategies for Protein Cryocrystallography Cryst. Growth Des. 2014, 14, 427-435 10.1021/cg301531f
49. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125-132 10.1107/S0907444909047337
50. Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 355-367 10.1107/S0907444911001314
51. Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 suite and current developments Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 235-242 10.1107/S0907444910045749
52. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501 10.1107/S0907444910007493
53. Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L.-W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 213-221 10.1107/S0907444909052925
54. Stura, E. A.; Wilson, I. A. Applications of the streak seeding technique in protein crystallization J. Cryst. Growth 1991, 110, 270-282 10.1016/0022-0248(91)90896-D